NewBiologix, a technology innovation company enabling efficient, cost-effective, and scalable production of viral vectors for cell and gene therapy (C&GT), has granted a non-exclusive technology license to Recipharm’s Advanced Therapies (ATMP) division (ReciBioPharm) to provide global biotech and pharma companies with access to NewBiologix’s Xcell-Eng-HEK293 cell lines.

NewBiologix provides cGMP-ready, high-yield, viral particle-producing cell lines and manufacturing technologies for developing gene therapies. This cell line enables customers to speed up development and advance C&GT programs to clinical trials. 

The Xcell-Eng-HEK293 cell lines are high-value solutions for manufacturing recombinant adeno-associated viruses (rAAV) for use in C&GT. 

As a result of proprietary innovations and sustained process development efforts using NewBiologix’s cell lines, ReciBioPharm has achieved industry-leading results across multiple AAV programs. It consistently exceeds 2E15 vg/L, even with large (~5kb) gene-of-interest constructs, demonstrating remarkable process robustness and reproducibility. 

In addition, ReciBioPharm has validated high-yield, high-purity AAV production across more than 10 rAAV serotypes, supporting broad therapeutic applicability. 

Its fully integrated offering, from research-use only (RUO) through to GMP manufacturing, provides a seamless, scalable path to clinic and market for advanced therapy developers.

Igor Fisch, CEO and co-founder of NewBiologix, said, “Core to this offering is our Xcell-Eng-HEK293 cell line, complemented with advanced analytics to guarantee the highest quality AAV for transformative therapeutic solutions.”

Vikas Gupta, President of ReciBioPharm, commented, “Our technology licensing agreement with NewBiologix for the Xcell-Eng-HEK293 cell line strengthens our position in the AAV space. Together, we advance the needs of our customers by driving down the costs of developing and manufacturing high quality AAV therapies.”